Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 168,262 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 168,262 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $0.72, for a total value of $121,148.64. Following the completion of the sale, the director owned 1,785,687 shares in the company, valued at approximately $1,285,694.64. The trade was a 8.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Stock Performance

HOWL traded down $0.03 during trading on Monday, hitting $0.69. 199,935 shares of the stock were exchanged, compared to its average volume of 410,071. The firm has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $0.88. The firm has a market cap of $33.53 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.14. As a group, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in HOWL. Regal Investment Advisors LLC boosted its position in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its position in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC boosted its position in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.